SEC Company Response from Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114) (ARMP) — Nov 10, 2016
Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114)
Date: Nov. 10, 2016 · CIK: 0000921114 · Accession: 0001144204-16-133415
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-213421
Letter
VIA EDGAR Division of Corporation Finance Attention: Ms. Suzanne Hayes Ms. Christina Thomas Re: AmpliPhi Biosciences Corporation — Request for Acceleration Registration Statement on Form S-1, as amended File No. 333-213421
Dear Ms. Hayes and Ms. Thomas:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), we hereby join in the request of AmpliPhi Biosciences Corporation (the “Company”) that the effective date of the above-captioned Registration Statement, as then amended, be accelerated so that it will become effective at 4:30 p.m., Eastern Time, on November 14, 2016, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that we have effected the distribution of approximately 450 copies of the Company’s preliminary prospectus, dated November 10, 2016, through the date hereof, to prospective underwriters, dealers, institutional investors and others.
We advise that we have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very Truly Yours,
By: ROTH CAPITAL PARTNERS, LLC
Show Raw Text
CORRESP
1
filename1.htm
ROTH CAPITAL PARTNERS, LLC
57 West 57th Street, 18th
Floor
New York, New York 10019
November 10, 2016
VIA EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Attention:
Ms. Suzanne Hayes
Ms. Christina Thomas
Re: AmpliPhi Biosciences Corporation — Request for
Acceleration
Registration
Statement on Form S-1, as amended
File
No. 333-213421
Dear Ms. Hayes and Ms. Thomas:
Pursuant to Rule 461 under the Securities
Act of 1933, as amended (the “Securities Act”), we hereby join in the request of AmpliPhi Biosciences Corporation (the
“Company”) that the effective date of the above-captioned Registration Statement, as then amended, be accelerated so
that it will become effective at 4:30 p.m., Eastern Time, on November 14, 2016, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities
Act, please be advised that we have effected the distribution of approximately 450 copies of the Company’s preliminary prospectus,
dated November 10, 2016, through the date hereof, to prospective underwriters, dealers, institutional investors and others.
We advise that we have complied and will
continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very Truly Yours,
By: ROTH CAPITAL PARTNERS, LLC
By:
/s/ Aaron M. Gurewitz
Name: Aaron M. Gurewitz
Title: Head of Equity Capital Markets